Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the ...

In the 106-patient study, those receiving 300mg of Dupixent every two weeks achieved a fivefold higher rate of sustained disease remission (20%) compared to placebo at 4%. Remission was defined as ...